PROSPECTIVE TRIAL OF INTRAOPERATIVE MITOMYCIN-C IN THE TREATMENT OF PRIMARY PTERYGIUM
PROSPECTIVE TRIAL OF INTRAOPERATIVE MITOMYCIN-C IN THE TREATMENT OF PRIMARY PTERYGIUM
复制标题
DOI：
10.1136/bjo.79.5.439
复制
发表时间：
1995-05-01
影响因子：
4.1
通讯作者：
MENEZO, JL
中科院分区：
文献类型：
--
作者：
CANOPARRA, J;DIAZLLOPIS, M;MENEZO, JL
目的——进行一项术中丝裂霉素C辅助治疗原发性翼状胬肉的前瞻性、随机、双盲、安慰剂对照研究。方法——对54例原发性翼状胬肉患者的66只眼进行切除治疗，术中单次应用丝裂霉素C（0.1mg/ml，5分钟），评价其疗效和毒性。 辅助治疗。平均随访时间为 14.1 个月（范围 12-23 个月）。 结果 - 在接受简单切除的 36 只眼中，14 只（38.8%）出现复发，而接受切除和术中应用丝裂霉素 C 治疗的 30 只眼中只有 1 只（3.33%）出现复发（p=0.0006）。丝裂霉素 C 治疗组未发现严重的眼部并发症或全身毒性。结论：术中丝裂霉素 C 似乎是原发性翼状胬肉的有效且安全的辅助治疗。
Aims-A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted.Methods-A total of 66 eyes of 54 patients with primary pterygium were treated with excision, with or without a single intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months).Results-Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited recurrences whereas only one of 30 eyes (3.33%) treated with excision and intraoperative application of mitomycin C had recurrence (p=0.0006). Neither serious ocular complications nor systemic toxicity were noted in the mitomycin C treated group.Conclusion-Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.